跳至主要内容
临床试验/NCT00590850
NCT00590850已完成不适用

A Multicenter, Prospective, Randomized Trial of Non-Operative Versus Operative Treatment for High-Energy Midshaft Clavicle Fractures

Prisma Health-Upstate2 个研究点 分布在 1 个国家目标入组 412 人开始时间: 2003年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
412
试验地点
2
主要终点
Disability of Arm, Shoulder and Hand (DASH) scores

研究概览

简要总结

Clavicle (collar bone) fractures account for about 33% of all fractures around the shoulder. Some surgeons suggest that surgical treatment is the best option, while others suggest that nonoperative care is the best treatment. There is no evidence to date that either option in superior. For this reason, we propose to conduct a prospective, randomized clinical trial of surgical versus non-surgical treatment of displaced high-energy clavicle fractures. This study will use both objective clinical and patient-based outcome measures. The purpose of this study is to see if there is a difference between clinical outcomes (healing rate, time to healing, time to return to work, Constant Score, complications), functional outcomes (DASH Score), and health related quality of life (SF-36) in nonoperative care and two types of surgical care for displaced fractures of the clavicular shaft in adults.

Included patients will be randomized into one of three groups: nonoperative care (Group N); surgical care using plates and screws (Group P); and surgical care using intramedullary pin put inside of the clavicle to stabilize it (Group I).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ages of 18 and 85
  • a midshaft clavicle fracture
  • fracture displaced the width of the clavicle or shortened at least 1.5 cm
  • less than 21 days since the injury

排除标准

  • injury involving the lateral ligaments
  • fracture involve the sternoclavicular joint
  • Pathologic Fracture
  • Open Fracture
  • Fracture with neurovascular compromise
  • Displaced fracture with impending skin compromise
  • Medical comorbidities that preclude surgery
  • Associated injuries to ipsilateral shoulder girdle
  • severe cognitive disability or injury that may inhibit study form completion

结局指标

主要结局

Disability of Arm, Shoulder and Hand (DASH) scores

时间窗: 1 year

Disability of Arm, Shoulder and Hand (DASH) scores

次要结局

  • Reoperation rate(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
1 期
A Phase III, Randomized, Open-Label, 3-Arm Study To Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation (IFM 07-01) - FIRSTMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaMultiple Myeloma
EUCTR2007-004823-39-ITCelgene Corporation1,590
进行中(未招募)
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 14.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2008-007803-10-BGWyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company479
进行中(未招募)
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancer
EUCTR2008-007803-10-FRWyeth Research, Division of Wyeth Pharmaceuticals, Inc.1,200
进行中(未招募)
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerEstudio de fase 3, aleatorizado, abierto y de dos grupos, de neratinib más paclitaxel versus trastuzumab más paclitaxel como tratamiento de primera línea en el cáncer de mama localmente recurrente o metastático positivo para ErbB-2ErbB2 Positive Locally Recurrent or Metastatic Breast CancerCáncer de mama localmente recurrente o metastático positivo para erbB-2.MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancer
EUCTR2008-007803-10-ESWyeth Research, Division of Wyeth Pharmaceuticals, Inc.1,200
进行中(未招募)
1 期
A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast CancerErbB2 Positive Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancer
EUCTR2008-007803-10-GRWyeth Research, Division of Wyeth Pharmaceuticals, Inc.479
Non-Operative Versus Operative Treatment for... | 临床试验